Concurrent Chemoradiotherapy with Paclitaxel and Cisplatin for Adenocarcinoma of the Cervix
Anticancer Research, 04/09/2012
Nagai Y et al. – The present study demonstrated that cisplatin–based concurrent chemoradiotherapy (CCRT)–TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence.
The authors retrospectively analyzed data for 32 patients with stage IIB–IVA cervical adenocarcinoma who were treated with radiotherapy (RT) or CCRT.
Fourteen patients were treated with RT, 8 with CCRT using cisplatin alone (CCRT-P), and 10 with CCRT using cisplatin plus paclitaxel (CCRT-TP).
Complete response was achieved in 7/14 patients in the RT group, 4/8 patients in the CCRT-P group, and 9/10 patients in the CCRT-TP group.
Ten out of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP groups experienced locoregional recurrence.
The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p=0.0094).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.